S
Stéphane Jouneau
Researcher at University of Rennes
Publications - 250
Citations - 4591
Stéphane Jouneau is an academic researcher from University of Rennes. The author has contributed to research in topics: Medicine & Idiopathic pulmonary fibrosis. The author has an hindex of 29, co-authored 205 publications receiving 3075 citations. Previous affiliations of Stéphane Jouneau include Paris Descartes University & EHESP.
Papers
More filters
Journal ArticleDOI
Eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): Clinical characteristics and long‐term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort
Cloé Comarmond,Christian Pagnoux,Mehdi Khellaf,Jean-François Cordier,Mohamed Hamidou,Jean-François Viallard,François Maurier,Stéphane Jouneau,Boris Bienvenu,Xavier Puéchal,Olivier Aumaître,Guillaume Le Guenno,Alain Le Quellec,Ramiro Cevallos,Olivier Fain,Bertrand Godeau,Raphaèle Seror,Bertrand Dunogué,Alfred Mahr,Philippe Guilpain,Pascal Cohen,Achille Aouba,Luc Mouthon,Loïc Guillevin +23 more
TL;DR: Although EGPA relapses remain frequent, mortality has declined, at least since 1996, and multivariable analysis identified cardiomyopathy, older age, and diagnosis during or prior to 1996 as independent risk factors for death and lower eosinophil count at diagnosis as predictive of relapse.
Journal ArticleDOI
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Athol U. Wells,Kevin R. Flaherty,Kevin K. Brown,Yoshikazu Inoue,Anand Devaraj,Luca Richeldi,Teng Moua,Bruno Crestani,Wim A. Wuyts,Susanne Stowasser,Manuel Quaresma,Rainer Georg Goeldner,Rozsa Schlenker-Herceg,Martin Kolb,S. Abe,Myriam Aburto,O. Acosta,C. Andrews,Danielle Antin-Ozerkis,G. Arce,M. Arias,Sergey Avdeev,A. Barczyk,Rebecca Bascom,E. Bazdyrev,Paul Beirne,E. Belloli,M. A. Bergna,E. Bergot,Nitin Y. Bhatt,S. Blaas,Benjamin Bondue,Francesco Bonella,E. Britt,Ketan P. Buch,J. Burk,H. Cai,A. Cantin,D. M. Castillo Villegas,A. Cazaux,S. Cerri,S. Chaaban,Nazia Chaudhuri,Vincent Cottin,B. Crestani,G. Criner,Caroline Dahlqvist,Sonye K. Danoff,J. Dematte D'Amico,Daniel F. Dilling,P. Elias,Neil Ettinger,J. Falk,E. R. Fernández Pérez,A. Gamez-Dubuis,G. Giessel,A. Gifford,Marilyn K. Glassberg,C. Glazer,J. Golden,L. Gómez Carrera,Julien Guiot,R. Hallowell,H. Hayashi,J. Hetzel,Nik Hirani,L. Homik,Ben Hope-Gill,D. Hotchkin,K. Ichikado,M. Ilkovich,Y. Inoue,S. Izumi,E. Jassem,L. Jones,Stéphane Jouneau,Robert J. Kaner,J. Kang,T. Kawamura,Romain Kessler,Y. Kim,K. Kishi,H. Kitamura,M. Kolb,Y. Kondoh,C. Kono,D Koschel,Michael Kreuter,Tejaswini Kulkarni,J. Kus,F. Lebargy,A. León Jiménez,Q. Luo,Yolanda Mageto,Toby M. Maher,S. Makino,Sylvain Marchand-Adam,C. Marquette,R. Martinez,M. Martínez,R. Maturana Rozas,Y. Miyazaki,Sergey Moiseev,Maria Molina-Molina,Lake Morrison,L. Morrow,T. Moua,Anoop M. Nambiar,Yasuhiko Nishioka,Hilario Nunes,M. Okamoto,Justin M. Oldham,Maria Otaola,Maria Padilla,J. S. Park,Nina Patel,Alberto Pesci,W. Piotrowski,L. Pitts,H. Poonyagariyagorn,Antje Prasse,Silvia Quadrelli,W. Randerath,R. Refini,M. Reynaud-Gaubert,F. Riviere,J. A. Rodríguez Portal,Ivan O. Rosas,M. Rossman,Zeenat Safdar,T. Saito,N. Sakamoto,M. Salinas Fénero,J. Sauleda,Shelley L. Schmidt,Mary Beth Scholand,M. Schwartz,Shane Shapera,Oksana A. Shlobin,B. Sigal,A. Silva Orellana,Dirk Skowasch,J. W. Song,S. Stieglitz,Helen Stone,Mary E. Strek,T. Suda,H. Sugiura,H. Takahashi,H. Takaya,T. Takeuchi,Krishna Thavarajah,Leslie Tolle,S. Tomassetti,K. Tomii,Claudia Valenzuela,Carlo Vancheri,F. Varone,Srihari Veeraraghavan,A. Villar,S. Weigt,L. Wemeau,W. Wuyts,Z. Xu,V. Yakusevich,Y. Yamada,H. Yamauchi,D. Ziora +167 more
TL;DR: The INBUILD trial suggests that nintedanib reduces the rate of ILD progression, as measured by FVC decline, in patients who have a chronic fibrosing ILD and progressive phenotype, irrespective of the underlying ILD diagnosis.
Journal ArticleDOI
Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome.
Isabelle Marie,Séverine Josse,Olivier Decaux,Stephane Dominique,E. Diot,Cédric Landron,P. Roblot,Stéphane Jouneau,P.Y. Hatron,K.P. Tiev,Olivier Vittecoq,D. Noel,Luc Mouthon,Jean-François Ménard,Fabienne Jouen +14 more
TL;DR: Although anti-Jo1 positive patients with ASS share some features with those with anti-PL7/PL12 antibody, they exhibit many differences regarding clinical phenotype and long-term outcome, underscores that the presence of anti- Jo1 antibody results in more severe myositis, joint impairment and increased risk of cancer.
Journal ArticleDOI
Incidence of Pneumocystis jiroveci Pneumonia among Groups at Risk in HIV-negative Patients
Pierre Fillatre,Olivier Decaux,Stéphane Jouneau,Matthieu Revest,Arnaud Gacouin,Florence Robert-Gangneux,Annie Fresnel,Claude Guiguen,Yves Le Tulzo,Patrick Jego,Pierre Tattevin +10 more
TL;DR: Estimates of incidence rates of pneumocystosis in HIV-negative patients admitted in the authors' institution, a referral center in the area, from January 1990 to June 2010 may be used as a guide to better target pneumocyStosis prophylaxis in the groups most at risk.
Journal ArticleDOI
Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis
Raphael Borie,Laure Tabèze,Gabriel Thabut,Hilario Nunes,Vincent Cottin,Sylvain Marchand-Adam,Grégoire Prévot,Abdellatif Tazi,Jacques Cadranel,Hervé Mal,Lidwine Wemeau-Stervinou,Anne Bergeron Lafaurie,Dominique Israel-Biet,Clément Picard,Martine Reynaud Gaubert,Stéphane Jouneau,Jean-Marc Naccache,Julie Mankikian,Christelle Ménard,Jean-François Cordier,Jean-François Cordier,Dominique Valeyre,Marion Reocreux,Bernard Grandchamp,Patrick Revy,Caroline Kannengiesser,Bruno Crestani +26 more
TL;DR: TERT/TERC DAV were associated with specific clinical and biological features and reduced transplant-free survival and the probability of DAV was increased for patients 40–60 years.